Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 2
2007 1
2009 1
2012 1
2013 1
2014 3
2015 1
2016 1
2017 1
2020 1
2021 2
2022 1
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
The need for a network to establish and validate predictive biomarkers in cancer immunotherapy.
Masucci GV, Cesano A, Eggermont A, Fox BA, Wang E, Marincola FM, Ciliberto G, Dobbin K, Puzanov I, Taube J, Wargo J, Butterfield LH, Villabona L, Thurin M, Postow MA, Sondel PM, Demaria S, Agarwala S, Ascierto PA. Masucci GV, et al. Among authors: villabona l. J Transl Med. 2017 Nov 3;15(1):223. doi: 10.1186/s12967-017-1325-2. J Transl Med. 2017. PMID: 29100546 Free PMC article.
Pembrolizumab for the First-Line Treatment of Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma: Results from the Single-Arm, Open-Label, Phase III KEYNOTE-913 Study.
Mortier L, Villabona L, Lawrence B, Arance A, Butler MO, Beylot-Barry M, Saiag P, Samimi M, Ascierto PA, Spada F, De Pontville M, Maio M, Berrocal A, Espinosa E, Capdevila J, Levin M, Das D, Krepler C, Grebennik D, Chiarion-Sileni V. Mortier L, et al. Among authors: villabona l. Am J Clin Dermatol. 2024 Nov;25(6):987-996. doi: 10.1007/s40257-024-00885-w. Epub 2024 Oct 8. Am J Clin Dermatol. 2024. PMID: 39377880 Free PMC article. Clinical Trial.
Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinoma.
Spassova I, Ugurel S, Kubat L, Zimmer L, Terheyden P, Mohr A, Björn Andtback H, Villabona L, Leiter U, Eigentler T, Loquai C, Hassel JC, Gambichler T, Haferkamp S, Mohr P, Pfoehler C, Heinzerling L, Gutzmer R, Utikal JS, Horny K, Schildhaus HU, Habermann D, Hoffmann D, Schadendorf D, Becker JC. Spassova I, et al. Among authors: villabona l. J Immunother Cancer. 2022 Jan;10(1):e003198. doi: 10.1136/jitc-2021-003198. J Immunother Cancer. 2022. PMID: 35074902 Free PMC article.
Prognostic Interactions between FAP+ Fibroblasts and CD8a+ T Cells in Colon Cancer.
Herrera M, Mezheyeuski A, Villabona L, Corvigno S, Strell C, Klein C, Hölzlwimmer G, Glimelius B, Masucci G, Sjöblom T, Östman A. Herrera M, et al. Among authors: villabona l. Cancers (Basel). 2020 Nov 3;12(11):3238. doi: 10.3390/cancers12113238. Cancers (Basel). 2020. PMID: 33153037 Free PMC article.
Clinical Categorization Algorithm (CLICAL) and Machine Learning Approach (SRF-CLICAL) to Predict Clinical Benefit to Immunotherapy in Metastatic Melanoma Patients: Real-World Evidence from the Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy.
Madonna G, Masucci GV, Capone M, Mallardo D, Grimaldi AM, Simeone E, Vanella V, Festino L, Palla M, Scarpato L, Tuffanelli M, D'angelo G, Villabona L, Krakowski I, Eriksson H, Simao F, Lewensohn R, Ascierto PA. Madonna G, et al. Among authors: villabona l. Cancers (Basel). 2021 Aug 19;13(16):4164. doi: 10.3390/cancers13164164. Cancers (Basel). 2021. PMID: 34439318 Free PMC article.
16 results